2026 Catch-up with Dexcom

We reflect on Dexcom's performance in 2025 and get up-to-date with news of their plans for a G8 sensor, international expansion and wearables.

Image courtesy of Dexcom Inc.

Dexcom has confirmed it is developing its next CGM sensor, not surprisingly called G8, while also setting out a strategy to grow internationally. This follows strong financial performance in 2025.

The company has stressed that G8 is under active development but not expected to launch in the near term - although there are unconfirmed rumours that this may be accelerated as recently there have been a number of user issues with the G7.

Plans for the G8 are understood to involve focusing on advancing performance, wearability and future capabilities.

Dexcom’s CEO, Jake Leach, has described G8 as a “whole new wearable”, explaining that the next generation is being designed to improve accuracy, reliability and connectivity, while also reducing sensor size.

Back in August 1925, Leach provided the insight that "the G8 will be 50% smaller and will include a chip that supports analyte sensing." This suggests ketone monitoring as Abbott, who are known to be currently developing a dual sensor and possibly a smaller sensor than the FreeStyle Libre 3 - we wait to see!

Dexcom has not yet announced a regulatory submission or launch date for G8.

Learning from challenges in 2025

Dexcom has acknowledged that 2025 presented operational challenges, including manufacturing scale-up pressures causing supply shortages of G7s and the complexity of rolling out new technology across multiple markets at once. All of which led to frustration for T1Ds using Dexcom's medtech. Company leadership has said these experiences are now shaping future decisions with new focus on improving manufacturing and supply chains.

Financial results

Dexcom's full-year 2025 accounts show global revenues of approximately £3.6 billion, an increase of around 16% year-on-year and in 2026 the company expects revenue to reach up to around £4.1 billion.

Leach, who officially became CEO on 1 January 2026, said the growth was driven by expanding Dexcom’s user base:

“We did this by adding a record number of new patients to Dexcom.”

At the year end Dexcom had around 3.5 million active customers, representing an increase of over 20% compared with the end of 2024.

UK data

The use of Dexcom products by type 1s is growing steadily in the UK, at the expense of FreeStyle Libre who dominate NHS prescriptions for CGM use by T1Ds. However, Dexcom only offers Dexcom One+ for use with MDI on the NHS.

Year	No. Dexcom One: NHS users (MDI)	No. Dexcom One+: NHS users (MDI)
2022/23	5,290	_
2023/24	17,124	_
2024/25	_	25,969

Dexcom is currently used by around 6% of T1Ds using a CGM only - FreeStyle Libre has 94% with around 380,000 users.

International focus

While Dexcom holds a strong position in the US CGM market, with a share of 44.7% in 2025, international markets remain a major opportunity. In regions such as Europe, Asia-Pacific and the Middle East & Africa, Dexcom is currently quite far behind market leader Abbott in terms of CGM distribution and use.

Speaking at the J.P. Morgan Healthcare Conference, Leach said:

“We've built our company based on leadership in the US, and we're now going to take that and apply it to the international markets, particularly our ability to open up access and coverage for people with CGM to unlock new opportunities that don’t exist today.”

A key part of this strategy will be the planned 2026 release of results from a large randomised controlled trial involving people with type 2 diabetes not using insulin. Leach said the data will “set the company up well” to support broader reimbursement and access internationally for this population.

The wider CGM market is forecast to continue expanding rapidly, with projected compound annual growth of 9.85%, reaching an estimated £12.2 billion global market value by 2035.

UK reassurance: Dexcom G6 remains available

For people using Dexcom's G6 CGM in the UK, Dexcom confirmed that it is not currently being withdrawn here.

Although Dexcom has announced plans to phase out G6 in the United States, with manufacturing there expected to end from July 2026, this transition is being managed on a country-by-country basis. In the UK, both Dexcom G6 and Dexcom G7 remain available, and there has been no announcement of an imminent withdrawal. This has also been confirmed by Prof Partha Kar, NHS T1 Diabetes Specialist for England.

Dexcom has stated that users in each market will receive advance notice before any changes to availability, allowing time for clinical discussion and transition planning where appropriate.

For now, UK users can continue using Dexcom G6 with confidence, while watching closely as Dexcom advances its international strategy and the longer-term development of its next-generation G8 sensor.

Expanding beyond CGM: Oura rings

Alongside its core CGM plans, Dexcom has also signalled its intention to expand into the wellness market, providing metabolic and health insights through a partnership with Oura.

Under the collaboration, Dexcom and Oura are working to integrate CGM data with Oura’s wearable metrics, such as sleep, activity, stress and recovery. The aim is to provide users with richer, context-aware insights into glucose trends, helping to explain how factors like sleep quality, illness, training load and daily stress interact with glucose levels.

The partnership is widely seen as part of Dexcom’s longer-term ambition to expand CGM beyond intensive insulin users, particularly into type 2 diabetes, metabolic health and preventative care markets. It also aligns with Dexcom’s emphasis on software, analytics and ecosystem partnerships as growth drivers alongside hardware innovation.

While timelines have not been confirmed, Dexcom has positioned the Oura partnership as a strategic foundation for future data-driven products, rather than a standalone consumer feature.

Interested in keeping up-to-date?

We'll be continuing to track all the news from Dexcom. If you'd like to be in the loop, ensure you subscribe to receive our free and independently edited newsletter, especially for CGM and pump users like you!

Click here to subscribe.

Disclaimer

Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️What CGM.

What CGM is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website www.whatcgm.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.

The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.